A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted

• Drug: ALO-02 weight-matched placebo
  
  crushed sugar spheres (powder) x 1 dose
• Drug: crushed ALO-02 30 mg/3.6 mg
  
  crushed ALO-02 30 mg/3.6 mg capsule x 1 dose
• Drug: oxycodone weight-matched placebo
  
  crushed lactose tablets (powder) x 1 dose
• Drug: crushed oxycodone IR 30 mg
  
  Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose

• Placebo Comparator: Treatment A
  
  Intervention: Drug: ALO-02 weight-matched placebo
• Experimental: Treatment B
  
  Intervention: Drug: crushed ALO-02 30 mg/3.6 mg
• Placebo Comparator: Treatment C
  
  Intervention: Drug: oxycodone weight-matched placebo
• Active Comparator: Treatment D
  
  Intervention: Drug: crushed oxycodone IR 30 mg

Inclusion Criteria:

• Healthy subjects
• Non-dependent, recreational opioid users. (Must use opioid for non-therapeutic purposes on at least 10 occassions within the last year and at least once in the 8 weeks before Visit 1 (Screening Visit).
• Must have experience with intranasal opioid administration (snorted opioid drugs on at least 3 occassions within the last year before Visit 1 (Screening Visit).

Exclusion Criteria:

• Diagnosis of substance and/or alcohol dependence
• Subject has participated in, is currently participating in, or seeking treatment for substance and/or alcohol related disorder.